Biocytogen Enters Platform Licensing Agreement with Taisho to Expand Use of RenNano® Antibody Discovery Technology
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company recognized for its innovation in antibody-based drug discovery, has announced a new strategic collaboration with Taisho Pharmaceutical Co., Ltd. Under this agreement, Taisho will gain access to Biocytogen’s proprietary RenNano® platform, a cutting-edge technology designed to enable the discovery and development of fully human heavy chain-only antibodies (HCAbs).
The licensing arrangement represents a significant step forward for both organizations, combining Biocytogen’s advanced antibody discovery capabilities with Taisho’s established research and development expertise. Together, the companies aim to accelerate the creation of next-generation biologic therapies across a range of therapeutic areas.
Expanding Access to RenNano® Technology
At the core of the agreement is Biocytogen’s RenNano® platform, an innovative system that utilizes genetically engineered mice to generate fully human heavy chain-only antibodies in vivo. Unlike conventional antibody formats, HCAbs are smaller and structurally distinct, offering unique advantages in terms of tissue penetration, stability, and the ability to target previously inaccessible epitopes.
Through this partnership, Taisho will be able to incorporate RenNano® mice into its internal discovery workflows. This will allow the company to efficiently generate and screen antibody candidates directly within a biological system, improving both the speed and quality of early-stage drug discovery.
In addition to antibody generation, the platform also supports downstream research processes, enabling seamless integration from discovery through to preclinical development. Although specific financial details of the agreement have not been disclosed, the collaboration underscores the growing demand for advanced antibody technologies in the global biopharmaceutical industry.
Driving Innovation in Antibody-Based Therapeutics
Biocytogen’s RenNano® platform is designed to address key challenges in antibody discovery by leveraging the natural immune response of engineered animal models. This approach enables the production of antibodies with high diversity, strong binding affinity, and favorable developability characteristics.
Heavy chain-only antibodies, particularly those derived from variable heavy-chain domains (VHHs), are gaining increasing attention for their versatility and therapeutic potential. Their compact size and simplified structure make them well suited for a variety of advanced modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and cell-based therapies such as CAR-T.
By adopting RenNano®, Taisho is expected to enhance its ability to explore these innovative therapeutic formats. The platform’s ability to generate fully human antibodies also reduces the need for subsequent humanization steps, streamlining development timelines and potentially lowering the risk of immunogenicity in clinical applications.
Strategic Benefits for Taisho
For Taisho Pharmaceutical, the agreement represents an opportunity to strengthen its research capabilities and expand its pipeline of biologic drug candidates. Access to RenNano® technology will allow the company to build a more efficient and integrated antibody discovery workflow, from initial target identification through to candidate optimization.
The use of in vivo systems for antibody generation offers a distinct advantage over traditional in vitro methods, as it captures the complexity of biological interactions and can yield antibodies with superior functional properties. This capability is particularly valuable in the development of therapies targeting complex or poorly understood disease mechanisms.
By leveraging Biocytogen’s platform, Taisho is positioning itself to accelerate innovation and remain competitive in an increasingly crowded and technologically advanced biopharmaceutical landscape.
Strengthening Biocytogen’s Global Partnership Network
For Biocytogen, the collaboration with Taisho marks another milestone in the expansion of its global partnership ecosystem. The company has been actively pursuing strategic alliances to broaden the adoption of its proprietary platforms and to establish itself as a key enabler of next-generation antibody discovery.
The RenNano® platform, in particular, has emerged as a cornerstone of Biocytogen’s offering, attracting interest from pharmaceutical and biotechnology companies worldwide. Its ability to generate fully human HCAbs with high specificity and affinity makes it a valuable tool for partners seeking to develop differentiated biologic therapies.
This latest agreement reinforces Biocytogen’s position as a leader in the field and highlights the growing recognition of its technologies within the global life sciences community.
Enabling Next-Generation Therapeutic Modalities
One of the most significant advantages of the RenNano® platform lies in its versatility. The antibodies generated through this system can be adapted for a wide range of therapeutic applications, including:
- Bispecific antibodies, which can simultaneously bind to two different targets, offering enhanced therapeutic efficacy
- Antibody-drug conjugates (ADCs), which deliver potent cytotoxic agents directly to diseased cells while minimizing off-target effects
- In vivo CAR-T therapies, which aim to engineer immune cells directly within the patient’s body, simplifying treatment logistics and expanding accessibility
These modalities represent some of the most promising frontiers in modern medicine, particularly in oncology, immunology, and rare diseases. By enabling the efficient discovery of high-quality antibody candidates, RenNano® supports the development of these advanced therapeutic approaches.
Leadership Perspective
Commenting on the collaboration, Biocytogen’s President and Chief Executive Officer, Dr. Yuelei Shen, emphasized the significance of the partnership and the capabilities of the RenNano® platform. He highlighted its robustness and efficiency in generating fully human VHH antibodies, noting that the technology provides a strong foundation for the development of innovative therapeutics.
Dr. Shen also expressed confidence that the collaboration would enhance Taisho’s research efforts, enabling the establishment of a more streamlined and effective antibody discovery workflow. This sentiment reflects the broader industry trend toward leveraging specialized platforms and partnerships to drive innovation and reduce development timelines.
As the biopharmaceutical industry continues to evolve, the demand for advanced discovery technologies is expected to grow. Platforms like RenNano® are playing an increasingly important role in enabling the development of novel therapies that address unmet medical needs.
The collaboration between Biocytogen and Taisho represents a strategic alignment of capabilities and resources, with the potential to yield significant advancements in antibody-based drug development. By combining cutting-edge technology with strong scientific expertise, the partnership is well positioned to contribute to the next wave of biologic innovation.
The platform licensing agreement between Biocytogen Pharmaceuticals and Taisho Pharmaceutical highlights the importance of technological innovation and strategic collaboration in modern drug discovery. Through access to the RenNano® platform, Taisho gains a powerful tool to enhance its research and development efforts, while Biocytogen continues to expand its global footprint and influence.
As both companies move forward with this partnership, the integration of RenNano® into Taisho’s workflows is expected to accelerate the discovery of fully human antibodies and support the development of next-generation therapeutics. Ultimately, this collaboration reflects a shared commitment to advancing science and improving patient outcomes through innovative biotechnology solutions.
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/ RenLite®/ RenNano®/RenTCR™/ RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration.
As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide.
Source Link:https://www.businesswire.com/
